Not only shouldn't postmenopausal women take hormone therapy to prevent heart disease, they shouldn't use it to improve or protect cognitive function, according to a large population-based study.
Researchers included 1,462 postmenopausal women residing in Wisconsin and participating in the 5-year follow-up examination for the Epidemiology of Hearing Loss Study in 19982000. Ninety-four of the women were cognitively impaired as defined by low Mini-Mental State Examination scores, with 20% of the 94 receiving a diagnosis of Alzheimer's disease.
After adjusting for age, current HT users were slightly less likely than nonusers to be cognitively impaired, but the finding was not statistically significant. Similarly, neither current, past, nor duration of HT use was associated with cognitive impairment. Age and educational attainment seem to play more important roles in postmenopausal cognitive status.
Mitchell JL, Cruickshanks KJ, Klein BE, et al. Postmenopausal hormone therapy and its association with cognitive impairment. Arch Intern Med. 2003;163:2485-2490.
Balancing VTE and bleeding risks in gynecologic cancer surgeries
December 6th 2024A comprehensive analysis shows the benefits of thromboprophylaxis often outweigh the bleeding risks during gynecologic cancer procedures, though patient-specific risk factors are crucial for decision-making.
Read More
Expert consensus sheds light on diagnosis and management of vasa previa
December 5th 2024A recent review established guidelines for prenatal diagnosis and care of vasa previa, outlining its definition, screening and diagnosis, management, and timing of delivery in asymptomatic patients.
Read More